About Systems Medicine (SM)
In July 2007, CTI acquired Systems Medicine (SM), a privately-held oncology company, in a stock-for-stock merger. SM applies a systems biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's context of vulnerability. Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs-the context of vulnerability.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.
This press release includes forward-looking statements that involve a
number of risks and uncertainties, the outcome of which could materially
and/or adversely affect actual future results. Specifically, the risks and
uncertainties that could affect the development of brostallicin include
risks associated with preclinical and clinical developments in the
biopharmaceutical industry in general and with brostallicin in particular
including, without limitation, the potential failure of brostallicin to
prove safe and effective for treatment of solid tumors, determinations by
regulatory, patent and administrative governmental authorities, competitive
factors, technological developments, costs of developing, producing and
selling brostallicin, and the risk factors listed or described from time to
|SOURCE Cell Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved